022) respectively (Figure CP-690550 manufacturer 1). Table 2 Univariable analysis of impact of pre-transplant variables on overall survival Variable Survival (% at 5 y)

Log rank P value Age at allo-HCT        < 40 28 0.055    ≥ 40 6   Diagnosis        MDS overt AML 0 0.015    Others 25   Cytogenetics        intermediate 35 0.013    poor 5   Marrow blasts at allo-HCT        ≤ 26 33 0.013    > 26 5   Donor source        Umbilical cord blood 0 <0.001    Others 22   Conditioning        Intensified 22 0.087    Standard 42      Reduced-intensity 0      Reduced-intensity + cytoreductive chemotherapy 7   allo-HCT: allogeneic hematopoietic cell transplantation Figure 1 Kaplan-Meier estimates of overall survival based on a landmark analysis at 6 months post-transplant, grouping TH-302 chemical structure this website patients according to prior history of cGVHD (p = .022). The 5-year survival rates of patients with and without prior history of cGVHD were 64% and 17%, respectively. Bivariable analysis

We performed the landmark analyses at 6 months post-transplant, which classified patients according to significant pre-transplant factors including poor-risk cytogenetics, number of BM blasts, or secondary leukemia and their prior history of cGVHD at 6 months post-transplant. Results of bivariable analysis for OS are shown in Figure 2, Figure 3 and Figure 4. The groups of patients with intermediate cytogenetics, Metformin marrow blast ≤ 26% or primary leukemia, who developed cGVHD less than 6

months after transplant, showed significantly or borderline significantly higher survival rates than those in the other groups (p = .039, p = .147, and p = .060, respectively). The five-year Kaplan-Meier estimates of OS in the patients with intermediate cytogenetics, marrow blast ≤ 26% or primary leukemia in addition to prior history of cGVHD were 75%, 83%, and 64%, respectively. Figure 2 Kaplan-Meier estimates of overall survival based on a landmark analysis at 6 months post-transplant, grouping patients according to cytogenetics and prior history of cGVHD (p = .039). The 5-year survival rates of patients with intermediate & prior history of cGVHD +, poor & prior history of cGVHD +, and poor & prior history of cGVHD – were 75%, 33%, and 20%, respectively. Figure 3 Kaplan-Meier estimates of overall survival based on a landmark analysis at 6 months post-transplant, grouping patients according to percent marrow blast (≤ or > 26%) at baseline and prior history of cGVHD (p = .147). Patients with CNS lesion were not included in this analysis. The 5-year survival rates of patients with fewer blast & prior history of cGVHD +, higher blast & prior history of cGVHD +, and fewer blast & prior history of cGVHD – were 83%, 33%, and 25%, respectively.